Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
401-420 of 936 trials

Rhabdomyosarcoma: New Treatment Combinations

We are studying new chemotherapy and radiotherapy options for children and adults with Rhabdomyosarcoma. The goal is to see if these new treatments improve outcomes compared to standard therapies.

RhabdomyosarcomaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Intranasal COVID-19 Vaccine: LVT-001

We are studying a new intranasal booster vaccine for COVID-19 to see if it is safe and more effective than the standard mRNA vaccine. This trial is for healthy adults who want to help improve COVID-19 vaccination strategies.

COVID-191-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

Advanced Solid Tumors: BT5528 Treatment Study

We are testing a new drug, BT5528, for patients with advanced solid tumors that express EphA2. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Soft Tissue Sarcomas: HDM201 and Pazopanib Study

We are evaluating a new treatment combining HDM201 and Pazopanib for patients with advanced soft tissue sarcomas. The goal is to understand its clinical impact on those with P53 wild-type tumors.

Soft Tissue Sarcoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Soft Tissue Sarcoma: MEK and PDL1 Inhibitor Combination

We are studying a new treatment combining two medications for patients with advanced soft tissue sarcoma. This trial aims to confirm safety and evaluate how well the treatment works in both children and adults.

Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

GEN1047 for Solid Tumors - First in Human Trial

We are testing a new treatment called GEN1047 for people with malignant solid tumors. The study aims to find the safest dose and evaluate how well it works against cancer.

Malignant Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Safety Study of IMP761 Immunosuppressive Antibody

We are testing the safety of a new immunosuppressive antibody in healthy volunteers. This study aims to understand how the antibody affects the body before further testing in patients.

Autoimmunity1-2 yearsSafety phase (I)Infectious Diseases

CART19 Cells for Blood Cancers

We are studying the effects of CART19 cells in patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. This research aims to explore new treatment possibilities for these challenging conditions.

Recurrent Acute Lymphoblastic Leukaemia>2 yearsSafety phase (I)HematologyOncology

IL12-L19L19 Treatment: Safety and Early Efficacy Study

We are investigating the safety and early signs of effectiveness of the IL12-L19L19 treatment. This study is for individuals who may benefit from new therapeutic options.

Advanced CarcinomaSafety phase (I)Oncology

Advanced Solid Tumors: PAS-004 Treatment Study

We are testing a new drug for patients with advanced solid tumors that have specific genetic mutations. The study aims to assess the safety and how the body handles this treatment in those who have not responded to other therapies.

Malignant Mast Cell Tumors>2 yearsSafety phase (I)Oncology

Glioblastoma Treatment: Olaptesed Pegol with Radiation

We are studying the safety and effectiveness of olaptesed pegol combined with radiation therapy for patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. This trial also explores how different doses may impact treatment outcomes.

Glioblastoma6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: IDE397 Treatment Study

We are evaluating a new drug, IDE397, for adults with advanced solid tumors to see how safe it is and how the body responds to it. This study aims to gather important information about its effects on cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Narcolepsy: Safety Study of Lu AH69593

We are testing a new medication to see how safe it is for healthy adults and those with narcolepsy. This study will help us understand how well the medication is tolerated.

Narcolepsy1-2 yearsSafety phase (I)Internal MedicineNeurology

Ovarian and Lung Cancer: TUB-040 Treatment Study

We are investigating a new antibody-guided drug for patients with therapy-resistant ovarian or lung cancer. The study aims to assess its safety and how well it works compared to existing treatments.

Platinum-Resistant High-Grade Ovarian Cancer and Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncologyPulmonology

B-Cell Blood Cancers: AZD5492 Treatment Study

We are investigating whether AZD5492 is safe and effective for adults with relapsed or refractory B-cell malignancies, both on its own and with other cancer treatments.

B-Cell Malignancies>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Parkinson’s Disease: RO7568282 Safety Study

We are testing a new drug, RO7568282, to see if it is safe for healthy people and those with Parkinson’s disease. This study will help us understand its effects on the body.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

Calcium Absorption: Glycocholate and Butyrate Study

We are testing the safety and tolerability of glycocholate and butyrate in healthy women who have undergone Roux-en-Y gastric bypass. This study aims to see if these substances can help improve calcium absorption.

Postoperative Obesity≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology

Ribociclib for Cancer Patients: Continued Access Study

We are offering patients who previously benefited from ribociclib the chance to continue treatment. This study also aims to collect important safety information about ribociclib alone or with other investigational therapies.

Advanced CancerSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

CD30-Positive Lymphoma: Brentuximab Imaging Study

We are investigating how a drug called Brentuximab distributes in the body of patients with CD30-positive lymphoma. This study may help improve future treatments for this type of cancer.

High-Risk Diffuse Large B-Cell LymphomaLymphoma>2 yearsSafety phase (I)HematologyOncology

Yellow Fever and Rabies: Investigational Vaccines

We are testing two new vaccines for yellow fever and rabies in healthy adults aged 18 to 40. The study aims to evaluate their safety and how well they trigger an immune response.

RabiesYellow FeverSafety phase (I)Infectious Diseases